@phdthesis{Berger2013,
  author    = {Berger, Susanne Andrea},
  title     = {Retrospektive Untersuchung {\"u}ber die Lebensqualit{\"a}t von Kindern und Jugendlichen mit prim{\"a}rer fokaler Hyperhidrose},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-104272},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2013},
  abstract  = {Die vorliegende Arbeit analysiert retrospektiv die funktionellen Beeintr{\"a}chtigungen und Einschr{\"a}nkungen der Lebensqualit{\"a}t von Kindern und Jugendlichen mit prim{\"a}rer fokaler Hyperhidrose. Grundlage der vorliegenden Untersuchung bildeten ein selbst entworfener Fragebogen sowie die Auswertung der Ambulanzkarten von 35 Kindern und Jugendlichen mit prim{\"a}rer fokaler Hyperhidrose im Alter von unter 18 Jahren, die sich im Zeitraum von Januar 2000 bis Dezember 2009 in der Hyperhidrose-Sprechstunde der Hautklinik des Universit{\"a}tsklinikums W{\"u}rzburg vorstellten. Die vorliegende Arbeit spezifiziert die t{\"a}glichen Einschr{\"a}nkungen, welche die Kinder und Jugendlichen erleben. F{\"u}r zwei Drittel der Patienten war das Schwitzen nach Maßgabe der Hyperhidrosis Disease Severity Scale kaum zu ertragen oder unertr{\"a}glich und beeintr{\"a}chtige h{\"a}ufig oder immer die t{\"a}glichen Aktivit{\"a}ten. Zwei Drittel der Patienten gaben an, derart stark unter der Krankheit zu leiden, dass sie ihre Lebensweise der Krankheit anpassten. Weiter konnte gezeigt werden, dass die Einschr{\"a}nkungen {\"a}hnlich gravierend sind wie bei Erwachsenen und anderen Dermatosen in der Kindheit. Die psychische und soziale Entwicklung kann bei einigen Betroffenen nachhaltig beeintr{\"a}chtigt werden, was sich auch auf das sp{\"a}tere Leben auswirken kann. Diese Erkenntnis ist wichtig, um eine fr{\"u}hzeitige Diagnose und ad{\"a}quate Behandlung voranzutreiben.},
  subject      = {Hyperhidrose},
  language  = {de}
}
@article{LjunggrenBarrettStoykovetal.2013,
  author    = {Ljunggren, Osten and Barrett, Annabel and Stoykov, Ivaylo and Langdahl, Bente L. and Lems, Willem F. and Walsh, J. Bernard and Fahrleitner-Pammer, Astrid and Rajzbaum, Gerald and Jakob, Franz and Karras, Dimitrios and Marin, Fernando},
  title     = {Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study},
  series = {BMC Musculoskeletal Disorders},
  volume    = {14},
  journal   = {BMC Musculoskeletal Disorders},
  number    = {251},
  issn      = {1471-2474},
  doi       = {10.1186/1471-2474-14-251},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-122057},
  year      = {2013},
  abstract  = {Background: To describe changes in health-related quality of life (HRQoL) of postmenopausal women with osteoporosis treated with teriparatide for up to 18 months and followed-up for a further 18 months, and to assess the influence of recent prior and incident fractures. Methods: The European Forsteo Observational Study (EFOS) is an observational, prospective, multinational study measuring HRQoL using the EQ-5D. The primary objective was to assess changes in HRQoL during 36 months in the whole study population. A secondary post-hoc analysis examined fracture impact on HRQoL in four subgroups classified based on recent prior fracture 12 months before baseline and incident clinical fractures during the study. Changes from baseline were analysed using a repeated measures model. Results: Of the 1581 patients, 48.4\% had a recent prior fracture and 15.6\% of these patients had an incident fracture during follow-up. 10.9\% of the 816 patients with no recent prior fracture had an incident fracture. Baseline mean EQ-VAS scores were similar across the subgroups. In the total study cohort (n = 1581), HRQoL (EQ-VAS and EQ-5D index scores) improved significantly from baseline to 18 months and this improvement was maintained over the 18-month post-teriparatide period. Improvements were seen across all five EQ-5D domains during teriparatide treatment that were maintained after teriparatide was discontinued. Subjects with incident clinical fractures had significantly less improvement in EQ-VAS than those without incident fractures. Recent prior fracture did not influence the change in EQ-VAS during treatment. Conclusions: EFOS is the first longitudinal study in women with severe postmenopausal osteoporosis in the real world setting to show a substantial improvement in HRQoL during teriparatide treatment that was sustained during subsequent treatment with other medications. The increase in HRQoL was lower in the subgroups with incident fracture but was not influenced by recent prior fracture. The results should be interpreted in the context of the design of an observational study.},
  language  = {en}
}
@article{EiseleBlozikStoerketal.2013,
  author    = {Eisele, Marion and Blozik, Eva and St{\"o}rk, Stefan and Tr{\"a}der, Jens-Martin and Herrmann-Lingen, Christoph and Scherer, Martin},
  title     = {Recognition of depression and anxiety and their association with quality of life, hospitalization and mortality in primary care patients with heart failure - study protocol of a longitudinal observation study},
  series = {BMC Family Practice},
  volume    = {14},
  journal   = {BMC Family Practice},
  number    = {180},
  issn      = {1471-2296},
  doi       = {10.1186/1471-2296-14-180},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121881},
  year      = {2013},
  abstract  = {Background: International disease management guidelines recommend the regular assessment of depression and anxiety in heart failure patients. Currently there is little data on the effect of screening for depression and anxiety on the quality of life and the prognosis of heart failure (HF). We will investigate the association between the recognition of current depression/anxiety by the general practitioner (GP) and the quality of life and the patients' prognosis. Methods/Design: In this multicenter, prospective, observational study 3,950 patients with HF are recruited by general practices in Germany. The patients fill out questionnaires at baseline and 12-month follow-up. At baseline the GPs are interviewed regarding the somatic and psychological comorbidities of their patients. During the follow-up assessment, data on hospitalization and mortality are provided by the general practice. Based on baseline data, the patients are allocated into three observation groups: HF patients with depression and/or anxiety recognized by their GP (P+/+), those with depression and/or anxiety not recognized (P+/-) and patients without depression and/or anxiety (P-/-). We will perform multivariate regression models to investigate the influence of the recognition of depression and/or anxiety on quality of life at 12 month follow-up, as well as its influences on the prognosis (hospital admission, mortality). Discussion: We will display the frequency of GP-acknowledged depression and anxiety and the frequency of installed therapeutic strategies. We will also describe the frequency of depression and anxiety missed by the GP and the resulting treatment gap. Effects of correctly acknowledged and missed depression/anxiety on outcome, also in comparison to the outcome of subjects without depression/anxiety will be addressed. In case results suggest a treatment gap of depression/anxiety in patients with HF, the results of this study will provide methodological advice for the efficient planning of further interventional research.},
  language  = {en}
}